Impact of the Clinicolaboratory Characteristics on the Treatment Outcome of the Pediatric Patients with Acute Lymphoblastic Leukemia at South Egypt Cancer Institute | ||||
| SECI Oncology Journal | ||||
| Article 1, Volume 3, Issue 2, March 2015, Page 55-63 PDF (354.33 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/secioj.2015.5698 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| BACKGROUND: In pediatric acute lymphoblastic leukemia (ALL), patients are treated according to risk groups defined by both clinical and laboratory features. We aimed at the identification of the nature of the clinical and laboratory features that our pediatric ALL patients possess at presentation and the determination of the impact of these features on the survival rates of them. METHODS: from January 2008 till January 2014, 172 pediatric patients (102 boys and 70 girls, age 2-15 years old) with newly diagnosed ALL who presented at the Pediatric Oncology Department, South Egypt Cancer Institute were analyzed for treatment outcome, disease free- and event free survival rates according to the presenting clinical and laboratory features. After being submitted for the standard diagnostic workup, the patients were assigned into standard and high risk groups. The response to treatment was estimated at the specified time points of the treatment protocol. The treatment outcome, overall - and event free survival rates were statistically calculated at the end of the study. RESULTS: favorable age group (2- < 10 years old) represented 76.2%. Mediastinal adenopathy and bulky extramedullary disease represented 9.9% and 14% respectively. Central nervous system (CNS) involvement with leukemia was encountered in 3.5% of the patients. Favorable initial WBC count (< 50.000 x109/μL) was found in 70.9%, and B-cell phenotype in 80.8% of patients. We found that favorable age, absence of certain clinical features as bulky disease; mediastinal adenopathy and CNS leukemia and presentation with favorable WBC count were all associated with remarkably higher remission rate and significantly lower relapse rate. DFS rate was significantly higher for patients presented at favorable age and for those who had no bulky disease or mediastinal adenopathy at presentation. CONCLUSION: this study showed that presentation with bulky extramedullary disease and mediastinal adenopathy can confer a negative impact on the remission rate and survival rates of the pediatric ALL patients treated at Pediatric Oncology Department, South Egypt Cancer Institute. It also showed that gender of the patients has no remarkable impact on the outcome of these patients. | ||||
| Keywords | ||||
| Acute lymphoblastic leukemia; bulky extramedullary disease; mediastinal adenopathy | ||||
|
Statistics Article View: 75 PDF Download: 141 |
||||
